Key result
Trial tests FFR-guided management vs angiography guidance for revascularization decisions in NSTEMI.
Why the study?
Does fractional flow reserve (FFR) disclosure increase the proportion of patients allocated to medical management only compared with revascularization in patients with acute NSTEMI?
RCT (n=350)
Open-label for FFR-guided group; patient and clinical team blinded to FFR recording in angiography-guided control group
1:1 parallel-group randomization using randomized permuted blocks
Yes
Does fractional flow reserve (FFR) disclosure increase the proportion of patients allocated to medical management only compared with revascularization in patients with acute NSTEMI?
This study protocol outlines the FAMOUS-NSTEMI trial, designed to establish the feasibility and impact of routine fractional flow reserve measurement on treatment decisions, clinical outcomes, and health care costs in patients with acute NSTEMI.
Answers are grounded in this paper and cite their sources.
No results yet from this NSTEMI FFR RCT; leaves open whether disclosure increases medical management allocation versus angiography guidance.
BACKGROUND: In patients with acute non-ST-elevation myocardial infarction (NSTEMI), coronary arteriography is usually recommended; but visual interpretation of the angiogram is subjective. We hypothesized that functional assessment of coronary stenosis severity with a pressure-sensitive guide wire (fractional flow reserve [FFR]) would have additive diagnostic, clinical, and health economic utility as compared with angiography-guided standard care. METHODS AND DESIGN: A prospective multicenter parallel-group 1:1 randomized controlled superiority trial in 350 NSTEMI patients with ≥1 coronary stenosis ≥30% severity (threshold for FFR measurement) will be conducted. Patients will be randomized immediately after coronary angiography to the FFR-guided group or angiography-guided group. All patients will then undergo FFR measurement in all vessels with a coronary stenosis ≥30% severity including culprit and nonculprit lesions. Fractional flow reserve will be disclosed to guide treatment in the FFR-guided group but not disclosed in the "angiography-guided" group. In the FFR-guided group, an FFR ≤0.80 will be an indication for revascularization by percutaneous coronary intervention or coronary artery bypass surgery, as appropriate. The primary outcome is the between-group difference in the proportion of patients allocated to medical management only compared with revascularization. Secondary outcomes include the occurrence of cardiac death or hospitalization for myocardial infarction or heart failure, quality of life, and health care costs. The minimum and average follow-up periods for the primary analysis are 6 and 18 months, respectively. CONCLUSIONS: Our developmental clinical trial will address the feasibility of FFR measurement in NSTEMI and the influence of FFR disclosure on treatment decisions and health and economic outcomes.
No takes yet. Share an insight, caveat, or question.
Berry et al. (2013) conducted an RCT in Acute non-ST-elevation myocardial infarction (NSTEMI) (n=350). Fractional flow reserve (FFR)-guided management (FFR disclosed to guide treatment; FFR <=0.80 indicates revascularization by PCI or CABG, FFR >0.80 indicates optimal medical therapy) vs. Angiography-guided standard care (FFR measured in all vessels >=30% stenosis but not disclosed to the clinical team or patient) was evaluated on Between-group difference in the proportion of patients allocated to medical management only compared with revascularization at baseline. Fractional flow reserve-guided management is being evaluated against angiography-guided standard care in 350 NSTEMI patients in this trial rationale and design paper, with no results reported yet.
Synapse has enriched 10 related papers. Consider them for comparative context: